Literature DB >> 19889937

Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain.

Meru Sheel1, Manisha Pandey, Michael F Good, Michael R Batzloff.   

Abstract

Streptococcus pyogenes, also known as group A streptococcus (GAS), is a human pathogen which infects people of all age groups. Previous work has reported that conformationally constrained chimeric peptide J8 protects against GAS challenge. In the current study, we demonstrate the utility of bioluminescent imaging as a rapid technique for monitoring bacterial dissemination following the passive transfer of rabbit anti-J8 antibodies to naïve mice and subsequent challenge with recombinant GAS strain M49, an emm type shown to be associated with poststreptococcal glomerular nephritis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889937      PMCID: PMC2812104          DOI: 10.1128/CVI.00256-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  30 in total

1.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

Authors:  R Kaul; A McGeer; A Norrby-Teglund; M Kotb; B Schwartz; K O'Rourke; J Talbot; D E Low
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Photonic detection of bacterial pathogens in living hosts.

Authors:  C H Contag; P R Contag; J I Mullins; S D Spilman; D K Stevenson; D A Benaron
Journal:  Mol Microbiol       Date:  1995-11       Impact factor: 3.501

3.  Passive transfer with serum and IgG antibodies of irradiated cercaria-induced resistance against Schistosoma mansoni in mice.

Authors:  B L Mangold; D A Dean
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

Review 4.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

5.  Complete genome sequence of an M1 strain of Streptococcus pyogenes.

Authors:  J J Ferretti; W M McShan; D Ajdic; D J Savic; G Savic; K Lyon; C Primeaux; S Sezate; A N Suvorov; S Kenton; H S Lai; S P Lin; Y Qian; H G Jia; F Z Najar; Q Ren; H Zhu; L Song; J White; X Yuan; S W Clifton; B A Roe; R McLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

6.  Survival, replication, and antibody susceptibility of Ehrlichia chaffeensis outside of host cells.

Authors:  Julia Shu-Yi Li; Gary M Winslow
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

7.  Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.

Authors:  Karen L Kotloff; Mary Corretti; Kathleen Palmer; James D Campbell; Mark A Reddish; Mary C Hu; Steven S Wasserman; James B Dale
Journal:  JAMA       Date:  2004-08-11       Impact factor: 56.272

8.  Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.

Authors:  D Bessen; V A Fischetti
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

9.  The dynamic nature of group A streptococcal epidemiology in tropical communities with high rates of rheumatic heart disease.

Authors:  M I McDonald; R J Towers; R Andrews; N Benger; P Fagan; B J Currie; J R Carapetis
Journal:  Epidemiol Infect       Date:  2007-05-31       Impact factor: 2.451

10.  Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci.

Authors:  S Pruksakorn; B Currie; E Brandt; D Martin; A Galbraith; C Phornphutkul; S Hunsakunachai; A Manmontri; M F Good
Journal:  Lancet       Date:  1994-09-03       Impact factor: 79.321

View more
  5 in total

1.  Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

Authors:  Michael R Batzloff; Anne Fane; Davina Gorton; Manisha Pandey; Tania Rivera-Hernandez; Ainslie Calcutt; Grace Yeung; Jon Hartas; Linda Johnson; Catherine M Rush; James McCarthy; Natkunam Ketheesan; Michael F Good
Journal:  Hum Vaccin Immunother       Date:  2016-08-19       Impact factor: 3.452

2.  Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.

Authors:  Manisha Pandey; Michelle N Wykes; Jon Hartas; Michael F Good; Michael R Batzloff
Journal:  J Immunol       Date:  2013-02-11       Impact factor: 5.422

3.  Modelling invasive group A streptococcal disease using bioluminescence.

Authors:  L E Lamb; X Zhi; F Alam; M Pyzio; C L Scudamore; S Wiles; S Sriskandan
Journal:  BMC Microbiol       Date:  2018-06-19       Impact factor: 3.605

4.  Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.

Authors:  Manisha Pandey; Jessica Powell; Ainslie Calcutt; Mehfuz Zaman; Zachary N Phillips; Mei Fong Ho; Michael R Batzloff; Michael F Good
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

5.  Non-invasive monitoring of Streptococcus pyogenes vaccine efficacy using biophotonic imaging.

Authors:  Faraz M Alam; Colin Bateman; Claire E Turner; Siouxsie Wiles; Shiranee Sriskandan
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.